Las ventas de fármacos para la enfermedad de Alzheimer en España han caído un 15% en la última década. Eso sí, nuestro consumo sigue siendo muy superior al de paises de nustro entorno como Francia, Alemania y Reino Unido, según un artículo recien publicado en la revista Jama Health Forum
Approximately 50 million people worldwide currently live with dementia, mainly Alzheimer disease (AD). Discovery of effective disease-modifying drugs remains elusive, and current AD pharmacotherapy relies on symptomatic drugs: acetylcholinesterase inhibitors (donepezil, rivastigmine, and galantamine) and antagonist of N-methyl-D-aspartate receptors (memantine).
Use of these drugs is debated owing to limited efficacy.
Ver:
Alzheimer: No Clinical Benefit From Drug Targeting Amyloid (Aduhelm)
Health authorities in France raised concerns about their use in 2011 and 2016, leading to their removal from the list of reimbursed drugs in 2018.
This cross-sectional study aimed to analyze 10-year trends in sales of AD drugs in France compared with trends in the UK, Spain, and Germany
Entradas
No hay comentarios:
Publicar un comentario